Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16836610 | 0.85 | SLC6A3 (0.51) | ALDH1A1SLC6A3SLC6A4LMNATSHR | |
| SCHEMBL2713939 | 0.84 | MAPT (0.44) | ALDH1A1CFTRHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL24009070 | 0.84 | ALDH1A1 (0.49) | ALDH1A1CFTRHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL30288409 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CFTRHSD17B10SLC6A3LMNA | |
| SCHEMBL24009066 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CFTRHSD17B10SLC6A3LMNA | |
| SCHEMBL1004686 | 0.81 | HSD17B10 (0.56) | ALDH1A1CFTRHSD17B10SLC6A3LMNA | |
| SCHEMBL29091602 | 0.80 | CYP1A2 (0.47) | ALDH1A1CFTRHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL24478646 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KMT2A | |
| SCHEMBL30516693 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KMT2A | |
| SCHEMBL26696240 | 0.78 | MAPT (0.51) | ALDH1A1CFTRHSD17B10SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
| CN-116601149-A | Aminoquinazoline derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022112490-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| CN-105579447-B | Ethynyl derivatives serving | 豪夫迈·罗氏有限公司 | 2018-11-13 | — | — | CN | disclosed |
| US-9676732-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-3049409-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114028-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3049409-A1 | ETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20160207890-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | disclosed |
| CN-105579447-A | Ethynyl derivatives | HOFFMANN LA ROCHE | 2016-05-11 | — | — | CN | disclosed |
| WO-2015044075-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207890-A1 | ETHYNYL DERIVATIVES | GRM2, GRIA4, GRM4 | ALDH1A1 1383/4885CFTR 921/4885HSD17B10 3125/4885 |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | ALDH1A1 1918/4885CFTR 21/4885HSD17B10 4815/4885 |
| US-20170114028-A1 | ETHYNYL DERIVATIVES | GRM2, GRIA4, GRM4 | ALDH1A1 1383/4885CFTR 921/4885HSD17B10 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.